[Minimally invasive treatment options for the management of benign prostatic hyperplasia].
Minimal-invasive Therapieoptionen zur Behandlung des benignen Prostatasyndroms.
Ablative techniques
Lower urinary tract symptoms
Minimally invasive treatment
Non-ablative procedures
Prostatic hyperplasia
Journal
Der Urologe. Ausg. A
ISSN: 1433-0563
Titre abrégé: Urologe A
Pays: Germany
ID NLM: 1304110
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
12
10
2021
pubmed:
6
11
2021
medline:
15
12
2021
entrez:
5
11
2021
Statut:
ppublish
Résumé
Benign prostatic hyperplasia is one of the most common diseases of aging men. Hyperplasia of the glandular tissue can cause distressing lower urinary tract symptoms, which can be treated with both drugs and interventions. For a long time, transurethral resection of the prostate and simple prostatectomy were considered the gold standard of surgical treatment. In order to be able to offer patients an outpatient treatment with few complications, shorter hospital stays and high efficiency, a variety of minimally invasive treatment options have been developed. While recommendations have already been made for the excision by focused waterjet, prostatic urethral lift, and prostatic artery embolization, there are several other very promising procedures for which, however, long-term data and data from comparative studies with reference procedures must still be awaited. Das benigne Prostatasyndrom ist eine der häufigsten Erkrankungen des alternden Mannes. Durch die Hyperplasie des Drüsengewebes können belastende Symptome des unteren Harntrakts entstehen, die sowohl medikamentös als auch interventionell therapiert werden können. Lange Zeit wurden dabei die transurethrale Resektion der Prostata und die suprapubische Adenomenukleation als Goldstandard der operativen Therapie angesehen. Um Patienten eine ambulante, komplikationsarme Therapie mit kürzeren Krankenhausaufenthalten und gleichzeitig hoher Effektivität anbieten zu können, wurde eine Vielzahl minimal-invasiver Therapieoptionen entwickelt. Während Empfehlungen bereits für die Exzision durch fokussierten Wasserstrahl, den prostatisch-urethralen Lift sowie die Prostataarterienembolisation ausgesprochen wurden, gibt es weitere vielversprechende Verfahren, für die jedoch noch Langzeitdaten und Daten aus Vergleichsstudien zu Referenzverfahren abgewartet werden müssen.
Autres résumés
Type: Publisher
(ger)
Das benigne Prostatasyndrom ist eine der häufigsten Erkrankungen des alternden Mannes. Durch die Hyperplasie des Drüsengewebes können belastende Symptome des unteren Harntrakts entstehen, die sowohl medikamentös als auch interventionell therapiert werden können. Lange Zeit wurden dabei die transurethrale Resektion der Prostata und die suprapubische Adenomenukleation als Goldstandard der operativen Therapie angesehen. Um Patienten eine ambulante, komplikationsarme Therapie mit kürzeren Krankenhausaufenthalten und gleichzeitig hoher Effektivität anbieten zu können, wurde eine Vielzahl minimal-invasiver Therapieoptionen entwickelt. Während Empfehlungen bereits für die Exzision durch fokussierten Wasserstrahl, den prostatisch-urethralen Lift sowie die Prostataarterienembolisation ausgesprochen wurden, gibt es weitere vielversprechende Verfahren, für die jedoch noch Langzeitdaten und Daten aus Vergleichsstudien zu Referenzverfahren abgewartet werden müssen.
Identifiants
pubmed: 34739566
doi: 10.1007/s00120-021-01702-6
pii: 10.1007/s00120-021-01702-6
doi:
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
1601-1611Informations de copyright
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132(3):474–479. https://doi.org/10.1016/S0022-5347(17)49698-4
doi: 10.1016/S0022-5347(17)49698-4
pubmed: 6206240
Egan KB (2016) The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 43(3):289–297. https://doi.org/10.1016/j.ucl.2016.04.001
doi: 10.1016/j.ucl.2016.04.001
pubmed: 27476122
Vuichoud C, Loughlin KR (2015) Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 22(1):1–6
pubmed: 26497338
Gravas S, Cornu JN, Gacci M et al (2021) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstructions (BPO). EAU Annual Congress Milan, 2021
Gratzke C, Schlenker B, Seitz M et al (2007) Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol 177(4):1419–1422. https://doi.org/10.1016/j.juro.2006.11.062
doi: 10.1016/j.juro.2006.11.062
pubmed: 17382744
Reich O, Gratzke C, Bachmann A et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 180(1):246–249. https://doi.org/10.1016/j.juro.2008.03.058
doi: 10.1016/j.juro.2008.03.058
pubmed: 18499179
Zhang Y, Yuan P, Ma D et al (2019) Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Prostate Cancer Prostatic Dis 22(4):493–508. https://doi.org/10.1038/s41391-019-0135-4
doi: 10.1038/s41391-019-0135-4
pubmed: 30816336
Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, Gontero P (2016) Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men’s ejaculatory function: time for a bespoke approach? Int J Urol 23(1):22–35. https://doi.org/10.1111/iju.12866
doi: 10.1111/iju.12866
pubmed: 26177667
Gravas S, Cornu JN, Drake M et al (2018) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)
Aoun F, Marcelis Q, Roumeguère T (2015) Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update. Res Rep Urol 7:125–136. https://doi.org/10.2147/RRU.S55340
doi: 10.2147/RRU.S55340
pubmed: 26317083
pmcid: 4547646
Gravas S, Cornu J, Gacci M et al (2019) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)
Armitage JN, Cathcart PJ, Rashidian A, De Nigris E, Emberton M, van der Meulen JHP (2007) Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J Urol 177(5):1619–1624. https://doi.org/10.1016/j.juro.2007.01.005
doi: 10.1016/j.juro.2007.01.005
pubmed: 17437773
MacRae C, Gilling P (2016) How I do it: aquablation of the prostate using the aquabeam system. Can J Urol 23(6):8590–8593
pubmed: 27995858
Müllhaupt G, Enzler-Tschudy A, Horg K et al (2021) Informative value of histological assessment of tissue acquired during aquablation of the prostate. World J Urol. https://doi.org/10.1007/S00345-020-03426-2
doi: 10.1007/S00345-020-03426-2
pubmed: 32902728
Gilling P, Barber N, Bidair M et al (2020) Three-year outcomes after aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol 27(1):10072–10079
pubmed: 32065861
Gross AJ, Lipp MJ, Baumbach R et al (2021) Rectal perforation after aquablation of the prostate: lessons learned the hard way. World J Urol. https://doi.org/10.1007/S00345-021-03660-2
doi: 10.1007/S00345-021-03660-2
pubmed: 33948694
Desai M, Bidair M, Zorn KC et al (2019) Aquablation for benign prostatic hyperplasia in large prostates (80–150 mL): 6‑month results from the WATER II trial. BJU Int 124(2):321–328. https://doi.org/10.1111/BJU.14703
doi: 10.1111/BJU.14703
pubmed: 30734990
Desai M, Bidair M, Bhojani N et al (2020) Aquablation for benign prostatic hyperplasia in large prostates (80–150 cc): 2‑year results. Can J Urol 27(2):10147–10153
pubmed: 32333733
Abt D, Hechelhammer L, Müllhaupt G et al (2018) Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 361:k2338. https://doi.org/10.1136/bmj.k2338
doi: 10.1136/bmj.k2338
pubmed: 29921613
pmcid: 6006990
Zhang JL, Wang MQ, Shen YG et al (2019) Effectiveness of contrast-enhanced MR angiography for visualization of the prostatic artery prior to prostatic arterial embolization. Radiology 291(2):370–378. https://doi.org/10.1148/radiol.2019181524
doi: 10.1148/radiol.2019181524
pubmed: 30806596
Zumstein V, Betschart P, Vetterlein MW et al (2019) Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 5(6):1091–1100. https://doi.org/10.1016/j.euf.2018.09.005
doi: 10.1016/j.euf.2018.09.005
pubmed: 30292422
Abt D, Müllhaupt G, Hechelhammer L et al (2021) Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2‑yr outcomes of a randomised, open-label, single-centre trial. Eur Urol 80(1):34–42. https://doi.org/10.1016/J.EURURO.2021.02.008
doi: 10.1016/J.EURURO.2021.02.008
pubmed: 33612376
Shim SR, Kanhai KJK, Ko YM, Kim JH (2017) Efficacy and safety of prostatic arterial embolization: systematic review with meta-analysis and meta-regression. J Urol 197(2):465–479. https://doi.org/10.1016/j.juro.2016.08.100
doi: 10.1016/j.juro.2016.08.100
pubmed: 27592008
Jiang YL, Qian LJ (2019) Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. BMC Urol. https://doi.org/10.1186/s12894-019-0440-1
doi: 10.1186/s12894-019-0440-1
pubmed: 31791304
pmcid: 6888906
Couture F, Belzile F, Noël-Lamy M, Ponsot Y, Tu LM (2020) Images—penile necrotic ulcer following prostatic artery embolization: a rare complication. Can Urol Assoc J 14(7):E347. https://doi.org/10.5489/CUAJ.6239
doi: 10.5489/CUAJ.6239
pubmed: 32017689
pmcid: 7337708
Moreira AM, de Assis AM, Carnevale FC, Antunes AA, Srougi M, Cerri GG (2017) A review of adverse events related to prostatic artery embolization for treatment of bladder outlet obstruction due to BPH. Cardiovasc Intervent Radiol 40(10):1490–1500. https://doi.org/10.1007/S00270-017-1765-3
doi: 10.1007/S00270-017-1765-3
pubmed: 28795212
McVary KT, Gange SN, Gittelman MC et al (2016) Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med 13(6):924–933. https://doi.org/10.1016/j.jsxm.2016.03.372
doi: 10.1016/j.jsxm.2016.03.372
pubmed: 27129767
McVary KT, Rogers T, Roehrborn CG (2019) Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4‑year results from randomized controlled study. Urology 126:171–179. https://doi.org/10.1016/j.urology.2018.12.041
doi: 10.1016/j.urology.2018.12.041
pubmed: 30677455
Parikh KA, Dora CD (2019) Holmium laser enucleation of the prostate after failed urolift: surgical considerations for the management of nonabsorbable implants. Urology 132:212. https://doi.org/10.1016/j.urology.2019.06.027
doi: 10.1016/j.urology.2019.06.027
pubmed: 31271781
Perera M, Roberts MJ, Doi SAR, Bolton D (2015) Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 67(4):704–713. https://doi.org/10.1016/j.eururo.2014.10.031
doi: 10.1016/j.eururo.2014.10.031
pubmed: 25466940
Woo HH, Bolton DM, Laborde E et al (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9(2):568–575. https://doi.org/10.1111/j.1743-6109.2011.02568.x
doi: 10.1111/j.1743-6109.2011.02568.x
pubmed: 22172161
Woo HH, Chin PT, McNicholas TA et al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82–88. https://doi.org/10.1111/j.1464-410X.2011.10342.x
doi: 10.1111/j.1464-410X.2011.10342.x
pubmed: 21554526
Roehrborn CG, Gange SN, Shore ND et al (2013) The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. study. J Urol 190(6):2161–2167. https://doi.org/10.1016/j.juro.2013.05.116
doi: 10.1016/j.juro.2013.05.116
pubmed: 23764081
McNicholas TA, Woo HH, Chin PT et al (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292–299. https://doi.org/10.1016/j.eururo.2013.01.008
doi: 10.1016/j.eururo.2013.01.008
pubmed: 23357348
Chin PT, Bolton DM, Jack G et al (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5–11. https://doi.org/10.1016/j.urology.2011.10.021
doi: 10.1016/j.urology.2011.10.021
pubmed: 22202539
Roehrborn CG, Barkin J, Gange SN et al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24(3):8802–8813
pubmed: 28646935
Gratzke C, Barber N, Speakman MJ et al (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2‑year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119(5):767–775. https://doi.org/10.1111/bju.13714
doi: 10.1111/bju.13714
pubmed: 27862831
Rukstalis D, Grier D, Stroup SP et al (2019) Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the MedLift study. Prostate Cancer Prostatic Dis 22(3):411–419. https://doi.org/10.1038/s41391-018-0118-x
doi: 10.1038/s41391-018-0118-x
pubmed: 30542055
Porpiglia F, Fiori C, Bertolo R et al (2018) 3‑Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int 122(1):106–112. https://doi.org/10.1111/bju.14141
doi: 10.1111/bju.14141
pubmed: 29359881
Kadner G, Valerio M, Giannakis I et al (2020) Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol 38(12):3235–3244. https://doi.org/10.1007/s00345-020-03140-z
doi: 10.1007/s00345-020-03140-z
pubmed: 32124019
Amparore D, De Cillis S, Volpi G et al (2019) First- and second-generation temporary Implantable nitinol devices as minimally invasive treatments for BPH-related LUTS: systematic review of the literature. Curr Urol Rep 20(8):47. https://doi.org/10.1007/s11934-019-0912-6
doi: 10.1007/s11934-019-0912-6
pubmed: 31278441
Porpiglia F, Fiori C, Amparore D et al (2019) Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int 123(6):1061–1069. https://doi.org/10.1111/bju.14608
doi: 10.1111/bju.14608
pubmed: 30382600
Magistro G, Stief CG, Gratzke C (2015) New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol 12(8):461–471. https://doi.org/10.1038/nrurol.2015.169
doi: 10.1038/nrurol.2015.169
pubmed: 26195444
Shim SR, Cho YJ, Shin IS, Kim JH (2016) Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol 48(1):19–30. https://doi.org/10.1007/s11255-015-1153-3
doi: 10.1007/s11255-015-1153-3
pubmed: 26560471
Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR (2013) Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol 189(4):1421–1426. https://doi.org/10.1016/j.juro.2012.11.003
doi: 10.1016/j.juro.2012.11.003
pubmed: 23142202
Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P (2011) Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 59(5):747–754. https://doi.org/10.1016/j.eururo.2010.11.024
doi: 10.1016/j.eururo.2010.11.024
pubmed: 21129846
Shore N, Tutrone R, Efros M et al (2018) Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol 36(5):801–809. https://doi.org/10.1007/s00345-018-2185-y
doi: 10.1007/s00345-018-2185-y
pubmed: 29380128
pmcid: 5916987